Aragen, a contract research, development and manufacturing organisation (CRDMO), has secured a $100 million investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of $1.4 bn, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors.

This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.